Search

Multifunctional magneto-plasmonic nanoparticles with magnetic hyperthermia and photothermal therapy could kill cancer cells efficiently. Herein, carbon-encapsulated Au/Fe3O4 (Au/Fe3O4@C) was fabricated using an enclosed flame spray pyrolysis. The nanostructures, including an Fe3O4 core (51.9–55.2 nm) with a decreasing carbon shell thickness and an Au core (4.68–8.75 nm) coated with 2–4 graphite layers, were tailored by tuning the C2H4 content in the reacting gas mixture. Saturation magnetization (33.7–48.2 emu/g) and optical absorption were determined. The carbon shell facilitated the dispersion of Au/Fe3O4 and restrained their laser-induced and magnetic field-induced coalescence and growth. Au/Fe3O4@C exhibited excellent magnetic resonance imaging capability (91.4 mM−1 s−1) and photothermal performance (65.4°C for 0.8 mg/mL Au/Fe3O4@C at a power density of 1.0 W/cm2 after 300 s near-IR laser irradiation (808 nm)). Moreover, the combined application of photothermal and magnetic-heating properties reduced the required intensity of both laser and magnetic field compared to the intensity of separate situations. Our work provides a unique, intriguing approach to preparing multicomponent core/shell nanoaggregates that are promising candidates for esophageal cancer cell therapy.

Background Hypermethylation of the CpG island in the promoter regions of tumor suppressor genes is common in the cancer tissue of non‐small cell lung cancer (NSCLC) patients. Epithelial cadherin (E‐cadherin) is a classic tumor suppressor gene of the cadherin superfamily and its promoter region is usually hypermethylated in malignant carcinomas. However, whether hypermethylation of the CpG island in the promoter region of E‐cadherin increases the risk of lung cancer is unknown. We conducted a meta‐analysis of E‐cadherin gene promoter methylation status in cancer tissue (CT) and autologous controls (AC). Methods Electronic databases were searched for E‐cadherin gene promoter methylation and NSCLC. The hypermethylation status between CT and AC of NSCLC patients were compared and pooled by random or fixed effect models according to statistical heterogeneity across the included studies. Results Eleven publications relevant to E‐cadherin gene promoter hypermethylation and lung cancer risk were identified and included. E‐cadherin gene promoter hypermethylation frequency in CT and AC was 0.32 (95% confidence interval [CI] 0.22–0.41) and 0.12 (95% CI 0.04–0.20), respectively, with statistical difference (P